ClinicalTrials.gg
RecruitingNCT06380426ObGeSemaUpdated Jun 24, 2026

A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity

An observational study in Monogenic Obesity, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know · 3 judgments

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
175
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris — 16 open to participants now, 16 under way, 1 of them phase 3. Obesity · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
10th of 20
175 · median 175
Started
2024
with 2 others
Observational
20 of 58
6 open now
Primary completion
2027-04
later than 6 of 15 live
Registered
51st of 58
by date

Among the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, this one is the 10th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2024, is one of 20 observational ones, reaches primary completion later than 6 of the 15 other live ones, and was the 51st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

16 of the 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Obesity by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Rare genetic forms of obesity, so called monogenic obesity are linked to alteration in energy balance involving hypothalamic pathways.

More than 60 genes encoding for proteins located in the hypothalamic leptin/melanocortin pathway have been described in the French National Protocol for Diagnostic and Care (PNDS).

While pathogenic and likely pathogenic variants in these genes are well-established causes of monogenic obesity, current evidence supports a broader genetic architecture of obesity, better understood as a continuum ranging from rare high-impact variants to polygenic susceptibility.

Variants of uncertain significance (VUS) as well as variants currently classified as benign or likely benign are frequently identified in clinical practice, and their classification may evolve over time as genomic databases expand and functional data accumulate In addition, polygenic background may interact with rare variants and contribute to the severity of the phenotype, disease progression, and therapeutic response.

The natural history of monogenic obesity is characterized by an early onset in childhood, with a major increase in weight in adolescence and young adulthood. The worsening of obesity exposes these patients to severe complications.

Severe obesity and eating disorders have a major impact on the quality of life of the person but also of the family and caregivers. Clinical management is complex and requires comprehensive, specialized and multidisciplinary management. The usual lifestyle approaches have so far shown disappointing results, similarly to bariatric surgery which leads to a more frequent weight regain in the situation of monogenic obesity, justifying new approaches.

In this context, evaluating the response to treatment in the particular condition of monogenic obesity is crucial to propose therapeutic options as early as possible to limit weight evolution and its complications.

GLP-1 (glucagon-like peptide 1) based innovative therapies have recently emerged as a promising option for treatment of obesity and its complications. This is the case for Semaglutide marketed as OZEMPIC® and WEGOVY®, developed by Novo Nordisk. However, there is a lack of data to confirm that semaglutide could be also effective in monogenic obesity.

The aim of the ObGeSema project is to set up a cohort composed of patients (1) having already initiated a treatment and (2) newly treated by Semaglutide in 21 pediatric and adult Specialized Obesity Centres (CSOs) and describe their evolution over a 4 years follow-up.

Read the detailed description

Rare genetic forms of obesity, so called monogenic obesity are linked to alteration in energy balance involving hypothalamic pathways. More than 60 genes encoding for proteins located in the hypothalamic leptin/melanocortin pathway have been described in the French National Protocol for Diagnostic and Care (PNDS) https://www.has-sante.fr/jcms/p_3280217/fr/generique-obesites-de-causes-rares).

While pathogenic and likely pathogenic variants in these genes are well-established causes of monogenic obesity, current evidence supports a broader genetic architecture of obesity, better understood as a continuum ranging from rare high-impact variants to polygenic susceptibility.

Variants of uncertain significance (VUS) as well as variants currently classified as benign or likely benign are frequently identified in clinical practice, and their classification may evolve over time as genomic databases expand and functional data accumulate In addition, polygenic background may interact with rare variants and contribute to the severity of the phenotype, disease progression, and therapeutic response.

The natural history of monogenic obesity is characterized by an early onset in childhood, with a major increase in weight in adolescence and young adulthood. The worsening of obesity exposes these patients to severe complications. Severe obesity and eating disorders have a major impact on the quality of life of the person but also of the family and caregivers. Clinical management is complex and requires comprehensive, specialized and multidisciplinary management. The usual lifestyle approaches have so far shown disappointing results, similarly to bariatric surgery which leads to a more frequent weight regain in the situation of monogenic obesity, justifying new approaches.

In this context, evaluating the response to treatment in the particular condition of monogenic obesity is crucial to propose therapeutic options as early as possible to limit weight evolution and its complications.

GLP-1 based innovative therapies have recently emerged as a promising option for treatment of obesity and its complications. This is the case for Semaglutide marketed as OZEMPIC® and WEGOVY®, developed by Novo Nordisk. However, there is a lack of data to confirm that semaglutide could be also effective in monogenic obesity, particularly across the full spectrum of genetic variants involved in the leptin-melanocortin pathway.

In France, semaglutide is currently accessible through several regulatory frameworks:

OZEMPIC® (up to 2 mg/week) is reimbursed by the French Social Security for the treatment of type 2 diabetes in adult patients.

WEGOVY® (up to 2.4 mg/week) was available through an Early Access Programme from May 2022 to September 2024 for adults with BMI >40 kg/m² and at least one comorbidity. Treatment initiated in this framework can be continued until December 2025.

Since November 2024, WEGOVY® (up to 2.4 mg/week) has had marketing authorization for the treatment of adolescents and adults ≥12 years with BMI ≥30 kg/m². However, the drug is not yet reimbursed, except in rare cases through individual exceptional reimbursement for rare and complex diseases.

Given this evolving regulatory landscape, it is essential to assess the real-life efficacy and safety of semaglutide in individuals with including both adolescents and adults carrying variants across the continuum of genetic susceptibility.

The aim of the ObGeSema project is to set up a cohort composed of patients (1) having already initiated a treatment and (2) newly treated by Semaglutide in 21 pediatric and adult Specialized Obesity Centres (CSOs) and describe their evolution over a 4 years follow-up.

03

Conditions studied

  • Monogenic Obesity

Browse trials for

Keywords

  • Monogenic obesity
  • Semaglutide
  • WEGOVY
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients (≥12 years) with monogenic obesity due to any variant regardless of pathogenicity classification and already treated or with the physician's decision to initiate treatment with Semaglutide in the standard care. Patients under legal protection and State Medical Assistance (AME) will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients (≥12 years) having already initiated a treatment with SEMAGLUTIDE (regardless of the context: early access, routine care, self-financing, or exceptional reimbursement) or with a physician's decision to initiate treatment in the standard care. All patients having initiated treatment will be proposed to participate, including those having already stopped the treatment at the time of study initiation.
  • Confirmation of monogenic obesity, as practiced in clinical routine, regardless of current classification (i.e., pathogenic, likely pathogenic, variant of uncertain significance [VUS], or benign) in a gene with leptin-melanocortin pathway described in PNDS (https://www.has-sante.fr/jcms/p_3280217/fr/generique-obesites-de-causes-rares). ) For patients with VUS or benign variants, inclusion is conditional on the availability of a polygenic risk score (PRS)
  • Patients duly informed and not objecting to participate in the study. For patients ≥12 years \<18 years Parents duly informed and not objecting that their child taking part in the study
  • Patients affiliated to a social security scheme or State Medical Assistance (AME).

Exclusion criteria

Exclusion Criteria:

  • Pregnant and breastfeeding women
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
175 participants (estimated)
Patient registry
No

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in weight and Body Mass Index (BMI)

    Percentage of subjects with a change in weight and Body Mass Index (BMI).Weight will be measured at initiation and at 12 months of the Semaglutide treatment

    Time frame: From baseline (T0) to T12

Secondary outcomes

  1. Change in weight and Body Mass Index (BMI)

    Percentage of subjects with a change in weight and Body Mass Index (BMI). Weight will be measured at initiation of the Semaglutide treatment and at each visit

    Time frame: From baseline (T0) to 6 and/or 24 and/or 36 and/or 48 and/or 60 months

  2. Reduction of body weight equal to or above 5%

    Percentage of subjects achieving a reduction of body weight equal to or above 5%(number of subjects with a % of body weight changes \> -5%)X100/ number of the total subject

    Time frame: From baseline (T0) to 6 and/or 12 and/or 24 and/or 36 and/or 48 and/or 60 months

  3. Change in Hunger score

    Number and percentage of subjects with change in Hunger score

    Time frame: From baseline (T0) to 12 and/or 24 and/or 36 and/or 48 and/or 60 months

  4. Change in eating behaviour measured by Food Craving questionnaire

    Number and percentage of subjects with change in Food Craving scale

    Time frame: From baseline (T0) to 12 months

  5. Change in eating behaviour measured by the Binge Eating Scale (BES)

    Number and percentage of subjects with change in Binge Eating Scale (BES)

    Time frame: From baseline (T0) to 12 months

  6. Change in eating behaviour measured by the Dutch Eating Behaviour Questionnaire (DEBQ)

    Number and percentage of subjects with change in Dutch Eating Behaviour Questionnaire (DEBQ)

    Time frame: From baseline (T0) to 12 months

  7. Change in eating behaviour measured by the Dykens questionnaire for ≥18 years patients

    Number and percentage of subjects with change in Hyperphagia score with the Dykens questionnaire for intellectual disability

    Time frame: From baseline (T0) to 12 months

  8. Change in eating behaviour measured by the Child Eating Behaviour Questionnaire (CEBQ)

    Number and percentage of subjects with change in the Child Eating Behaviour Questionnaire (CEBQ) for intellectual disability for ≥18 years patients

    Time frame: From baseline (T0) to 12 months

  9. Change in the International physical activity questionnaire (IPAQ - short form) for ≥18 years patients

    Number and percentage of subjects with change of the International physical activity

    Time frame: From baseline (T0) to 12 months

  10. Change in Digestive disorders (GIQLI ) for ≥18 years patients

    Number and percentage of subjects with change in Digestive disorders (GIQLI ). Digestive disorders are measured by the Gastrointestinal Quality of Life Index (GIQLI)

    Time frame: From baseline (T0) to 12 and/or 24 and/or 36 and/or 48 and/or 60 months

  11. Change in score of quality of life scores (patient and parents) for ≥18 years patients

    Number and percentage of subjects with change in score of quality of life scores .Quality of life is measured with the Impact of Weight on Quality of Life-Lite scale (IWQOL-Lite)

    Time frame: From baseline (T0) to 12 months

  12. Change in sleep disorder (MCTQ score) for ≥18 years patients

    Number and percentage of subjects with Change in sleep disorder. Sleep disorder is measured with the Micro Munich Chronotype Questionnaire (MCTQ)

    Time frame: From baseline (T0) to 12 months

  13. Change in anxiety and depression score for ≥18 years patients

    Number and percent of subjects with change in anxiety and depression score. Anxiety and depression is measured with the Hospital Anxiety and Depression scale (HAD)

    Time frame: From baseline (T0) to 12 and/or 24 and/or 36 and/or 48 and/or 60 months

  14. ● Change in Body Mass Index : BMI Z-score for 12 to <18 years

    Weight will be measured at initiation of the Semaglutide treatment and at each visit

    Time frame: From baseline (T0) to 6 and/or 12 and/or 24 and/or 36 and/or 48 and/or 60 months

  15. Change in eating behaviour scores CEBQ ( Child Eating Behaviour Questionnaire) or Hyperphagia score with the Dykens questionnaire and for intellectual disability. For 12 to <18 years patients

    Number and percentage of subjects with change

    Time frame: From baseline (T0) to 12 months

  16. Change in score of IWQOL Impact of Weight on Quality of Life (patient and parents). For 12 to <18 years patients

    Number and percentage of subjects with change in score Impact of Weight on Quality of Life

    Time frame: From baseline (T0) to 12 months

  17. Change in Digestive disorders GIQLI score (Gastrointestinal Quality of Life Index). For 12 to <18 years patients

    Number and percentage of subjects with change

    Time frame: From baseline (T0) to 12 and/or 24 and/or 36 and/or 48 and/or 60 months

  18. Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Number of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: From baseline (T0) to 6 and/or 12 and/or 24 and/or 36 and/or 48 and/or 60 months

07

Study locations

1 of 2 sites recruiting
  • Centre de référence Syndrome de Prader-Willi et autres obésités avec troubles du comportement alimentaire (PRADORT). Service de Nutrition, GH Pitié-Salpêtrière, APHP
    Paris, 75013, France
    Not yet recruiting
  • CHU Pitié Salpêtrière - APHP
    Paris, 75013, France
    Recruiting
    • Christine POITOU-BERNERT, MD, PhD · Contact+33(0)142175771
    • Christine POITOU-BERNERT, MD,PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodological sound proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Apr 2027, 31 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 31 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2024
First posted
Apr 23, 2024
StartActual
Sep 19, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06380426
Responsible party
Sponsor
First posted
Apr 23, 2024
Start date
Sep 19, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Christine POITOU-BERNERT, MD,PhD
Contact
christine.poitou-bernert@aphp.fr
+33(0)142175771
Sarra POCHON
Contact
sarra.pochon@aphp.fr
+33(0)142167574
Christine POITOU-BERNERT, MD,PhD
principal investigator · Assistance Publique - Hôpitaux de Paris
Béatrice DUBERN, MD,PhD
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion